A Dark Vector Cognition product

Item 6. Exhibits

18K characters. Original on sec.gov ·

Item 6. Exhibits

Exhibit No.Exhibit
3.1By-Laws of Abbott Laboratories, as amended and restated, effective April 24, 2026, filed as Exhibit 3.1 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
4.1Indenture, dated as of March 10, 2015, between Abbott Laboratories and U.S. Bank National Association (including form of security), filed as an exhibit to the Abbott Laboratories Current Report on Form 8-K filed on March 10, 2015, filed as Exhibit 4.1 to the Abbott Laboratories Current Report on Form 8-K filed on March 9, 2026.
4.2Officers’ Certificate Pursuant to Sections 3.1 and 3.3 of the Indenture with respect to the Floating Rate Notes due 2029, the 3.700% Notes due 2029, the 4.000% Notes due 2031, the 4.300% Notes due 2033, the 4.650% Notes due 2036, the 4.750% Notes due 2038, the 5.500% Notes due 2056 and the 5.600% Notes due 2066, filed as Exhibit 4.2 to the Abbott Laboratories Current Report on Form 8-K filed on March 9, 2026.
4.3Form of Floating Rate Notes due 2029, filed as Exhibit 4.3 to the Abbott Laboratories Current Report on Form 8-K filed on March 9, 2026 (included in Exhibit 4.2 of the Abbott Laboratories Current Report on Form 8-K filed on March 9, 2026).
4.4Form of 3.700% Notes due 2029, filed as Exhibit 4.4 to the Abbott Laboratories Current Report on Form 8-K filed on March 9, 2026 (included in Exhibit 4.2 of the Abbott Laboratories Current Report on Form 8-K filed on March 9, 2026).
4.5Form of 4.000% Notes due 2031, filed as Exhibit 4.5 to the Abbott Laboratories Current Report on Form 8-K filed on March 9, 2026 (included in Exhibit 4.2 of the Abbott Laboratories Current Report on Form 8-K filed on March 9, 2026).
4.6Form of 4.300% Notes due 2033, filed as Exhibit 4.6 to the Abbott Laboratories Current Report on Form 8-K filed on March 9, 2026 (included in Exhibit 4.2 of the Abbott Laboratories Current Report on Form 8-K filed on March 9, 2026).
4.7Form of 4.650% Notes due 2036, filed as Exhibit 4.7 to the Abbott Laboratories Current Report on Form 8-K filed on March 9, 2026 (included in Exhibit 4.2 of the Abbott Laboratories Current Report on Form 8-K filed on March 9, 2026).
4.8Form of 4.750% Notes due 2038, filed as Exhibit 4.8 to the Abbott Laboratories Current Report on Form 8-K filed on March 9, 2026 (included in Exhibit 4.2 of the Abbott Laboratories Current Report on Form 8-K filed on March 9, 2026).
4.9Form of 5.500% Notes due 2056, filed as Exhibit 4.9 to the Abbott Laboratories Current Report on Form 8-K filed on March 9, 2026 (included in Exhibit 4.2 of the Abbott Laboratories Current Report on Form 8-K filed on March 9, 2026).
4.10Form of 5.600% Notes due 2066, filed as Exhibit 4.10 to the Abbott Laboratories Current Report on Form 8-K filed on March 9, 2026 (included in Exhibit 4.2 of the Abbott Laboratories Current Report on Form 8-K filed on March 9, 2026).
10.1Abbott Laboratories 2026 Incentive Stock Program (incorporated by reference to Exhibit A of the Abbott Laboratories Definitive Proxy Statement on Schedule 14A filed on March 13, 2026).
10.2Form of Restricted Stock Unit Agreement (time-based vested) under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.2 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.3Form of Restricted Stock Unit Agreement for foreign employees (time-based vested) under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.3 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.4Form of Restricted Stock Unit Agreement (cliff vested) under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.4 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.5Form of Restricted Stock Unit Agreement for foreign employees (cliff vested) under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.5 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.6Form of Performance Restricted Stock Agreement (annual performance based) under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.6 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.7Form of Performance Restricted Stock Unit Agreement for foreign employees (annual performance based) under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.7 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.8Form of Performance Restricted Stock Agreement (interim performance based) under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.8 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.9Form of Performance Restricted Stock Unit Agreement for foreign employees (interim performance based) under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.9 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.10Form of Restricted Stock Agreement (time-based vested) under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.10 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.11Form of Restricted Stock Agreement (cliff vested) under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.11 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.12Form of Non-Qualified Stock Option Agreement under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.12 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.13Form of Non-Qualified Stock Option Agreement for foreign employees under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.13 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.14Form of Restricted Stock Unit Agreement for executive officers (cliff vested) under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.14 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.15Form of Restricted Stock Unit Agreement for foreign executive officers (cliff vested) under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.15 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.16Form of Performance Restricted Stock Agreement for executive officers (annual performance based) under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.16 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.17Form of Performance Restricted Stock Agreement for executive officers (interim performance based) under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.17 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.18Form of Performance Restricted Stock Unit Agreement for foreign executive officers (annual performance based) under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.18 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.19Form of Performance Restricted Stock Unit Agreement for foreign executive officers (interim performance based) under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.19 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.20Form of Restricted Stock Agreement for executive officers (time-based vested) under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.20 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.21Form of Restricted Stock Agreement for executive officers (cliff vested) under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.21 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.22Form of Non-Qualified Stock Option Agreement for executive officers under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.22 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.23Form of Non-Qualified Stock Option Agreement for foreign executive officers under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.23 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.24Form of Non-Employee Director Restricted Stock Unit Agreement under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.24 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.25Form of Non-Employee Director Restricted Stock Unit Agreement for foreign non-employee directors under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.25 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.26Form of Non-Employee Director Non-Qualified Stock Option Agreement under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.26 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
10.27Form of Non-Employee Director Non-Qualified Stock Option Agreement for foreign non-employee directors under the Abbott Laboratories 2026 Incentive Stock Program, filed as Exhibit 10.27 to the Abbott Laboratories Current Report on Form 8-K filed on April 27, 2026.
31.1Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
31.2Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.
32.1Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in Inline XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated Statement of Shareholders’ Investment; (v) Condensed Consolidated Statement of Cash Flows; and (vi) Notes to the Condensed Consolidated Financial Statements.
104Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ABBOTT LABORATORIES
By:/s/ PHILIP P. BOUDREAU
Philip P. Boudreau
Executive Vice President, Finance and Chief Financial Officer
Date: April 29, 2026

Previous: Item 1. Legal Proceedings